EP0354904A1 - Inositol phosphate analogues - Google Patents

Inositol phosphate analogues

Info

Publication number
EP0354904A1
EP0354904A1 EP88902179A EP88902179A EP0354904A1 EP 0354904 A1 EP0354904 A1 EP 0354904A1 EP 88902179 A EP88902179 A EP 88902179A EP 88902179 A EP88902179 A EP 88902179A EP 0354904 A1 EP0354904 A1 EP 0354904A1
Authority
EP
European Patent Office
Prior art keywords
inositol
general formula
formula
myo
zero
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88902179A
Other languages
German (de)
French (fr)
Inventor
B.V.L. The University Of Leicester Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3I Research Exploitation Ltd
Original Assignee
Research Corp Ltd
3I Research Exploitation Ltd
Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Ltd, 3I Research Exploitation Ltd, Research Corp filed Critical Research Corp Ltd
Publication of EP0354904A1 publication Critical patent/EP0354904A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/177—Esters of thiophosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to analogues of inositol phosphate esters and to a method for the preparation thereof.
  • Inositol [C 6 H 6 (OH) 6 ] is hexahydroxycyclohexane of which there are nine isomeric forms.
  • Myo- inositol is cis-1,2,3,5-trans-4,6-hexahydroxycyclohexane.
  • inositol phosphates are known, One well-known derivative of commercial importance is phytic acid (inositol hexaphosphoric acid). Also known are D-myo-inositol-1,3,4-trisphosphate , the 1,4,5-isomer and the 1,4,5,6- and 1,3,4,5-tetrakisphosphates. These molecules are of biological importance although their precise biological roles have not yet been fully elucidated. They may be isolated with some difficulty and in low yield from natural sources.
  • inositol phosphates The biological significance of inositol phosphates is the subject of much current interest and research.
  • One area in which the inositol phosphates have been found to be involved is in calcium ion transport mechanisms in cells.
  • an inositol phosphorothioate having the general formula I;
  • n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6.
  • the present invention provides an inositol molecule in which one or more of its six hydroxyl groups is esterified by a phosphorothioate group, the remaining positions being occupied by hydroxyl or phosphate ester groups.
  • the sulphur atom, of the thioate group may be a radioisotope of sulphur to provide radiolabelled compounds for use as research reagents.
  • the present invention also provides a method of preparing an inositol phosphorothioate having the general formula I;
  • n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6, said method comprising reacting an inositol derivative having the general formula II ;
  • n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with a solution of elemental sulphur in a solvent therefor, and removing the protecting groups from the product of the reaction.
  • the hydroxyl-protecting group represented by B in formula II is a benzyl group.
  • a divalent group such as isopropylidene may be utilised when n is an even number and the hydroxyl groups are thereby protected in pairs.
  • Bz is a benzyl group
  • iPr' is an isopropylidenyl group
  • n is zero or an integer from 1 to 5
  • m is zero or 1 or 2
  • p is 2 or 4 or 6.
  • the compound of general formula II above may be oxidised with, for example a hydroperoxide such as tert- butylhydroperoxide, to form a compound having the formula VI;
  • the starting material that is, the inositol derivative having the general formula II defined above, may be prepared by a method comprising reacting a compound having the general formula III:
  • the benzylated inositol starting material (formula III above) may be prepared from inositol, via the isopropylidene derivatives, according to the method described in J. Gigg, R. Gigg, S. Payne & R. Conant;
  • the present invention also provides a method of preparing an inositol phosphate having the general formula I;
  • n is zero or an integer from 1 to 5 and, m is zero, said method comprising reacting an inositol derivative having the general formula II; '
  • n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with an organic peroxide, and removing the protecting groups from the product of the reaction.
  • the organic preroxide is preferably tert-butyl hydroperoxide.
  • (+,-)- 1,2,4-tri-O-benzyl-myo-inositol (0.20 mmole) was treated with 0.66 mmole of chloro (2-cyanoethoxy)- N,N diisopropylamino phosphine and diisopropylethylamine ((0.60 mmole) in dichloromethane to yield the trisphosphoramidite.
  • Reaction of the trisphosphoramidite with tetrazole and 2-cyanoethanol yielded the trisphosphite triester in about 90% yield.
  • 31P NMR spectroscopy showed 5 Jpp spin-spin coupling in the form of an AB system for two of the phosphite triesters confirming the phosphitylation of the vicinal 4,5-diol system.
  • (+,-)-1,2,3,4-tetra-O-benzyl myo-inositol was treated with 2 equivalents of chloro(2-cyanoethoxy)- N,N diisopropylamino phosphine in dichloromethane to yield the bisphosphoramidite.
  • Treatment of the bisphosphoramidite with tetrazole and 2-cyanoethanol gave the bisphosphite triester.
  • 31 P NMR spectroscopy showed that about 90% of the phosphorus could be accounted for by an AB system assignable to the 4, 5-bis ⁇ hosphite triester system.
  • the 4,5-bisphosphite triester prepared as described in Example 2 above, was reacted with a solution of sulphur in pyridine to yield the bisphosphoro-thioate triester and subsequent removal of the protecting groups using sodium in liquid ammonia yielded (+,-)myo-inositol 4,5-bisphos ⁇ horothioate.
  • the sulphur may be radioactive.
  • (+ , -) -1,2,4,5-Bisisopropylidene-myo-inositol was reacted with chloro(2-cyanoethoxy)-N,N diisopropylamino phosphine (0.715 mmole) and diisopropylethylamine (0.715 mmole) in dichloromethane (1 ml) for one hour to yield the bisphosphoramidite.
  • Reaction of the phosphoramidite with tetrazole and 2-cyanoethanol (0.715 mmole of each) gave the 1,4-bisphosphite triester.
  • Oxidation with tert-butyl hydroperoxide (1 ml) gave the bisphosphate triester.
  • (+) -1,2,4-tri-O-benzyl-myo- inositol was converted to the corresponding tri [di(2-cyanoethyl)]phosphite via the phosphoramidite as previously described and then oxidised using sulphur in pyridine.
  • Complete deprotection of all the protecting groups was accomplished using sodium in liquid ammonia, the 2-cyanoethyl groups being removed by beta-elimination and the benzyl groups cleaved to yield a crude product.
  • the proton-coupled 31 P NMR spectrum was similar to that reported for authentic D-myo-inositol-1,4,5-trisphosphate and its synthetic DL-isomer except that the resonances were shifted about 40ppm downfield as would be expected for the phosphorothioates.
  • trisphosphorothioate In biological evaluation of trisphosphorothioate, using rat cerebellum membrane receptor-binding assay specific for myo-inositol-1,4,5-tris ⁇ hosphate, the trisphosphorothioate was found to have a high affinity for such receptors, indicating the potential of the sulphur analogues in studies on receptor-linked phosphoinositide metabolism. Additionally it was found to release calcium from permeablised cells as a full agonist with an EC 50 of only three times higher than the 1,4,5-trisphosphate. EXAMPLE 7
  • the bisphosphite triester (0.325 mmole) was oxidised to the bisphosphorothioate ester using sulphur (200 mg) in pyridine (2 ml). The reaction mixture was filtered, the liquid evaporated and the residue dissolved in methanol [d P (MeOH) 2s, 65.85, 67.41].
  • optical configuration of these products is determined by the optical configuration of the starting materials. If the precursors of the products are optically resolved, the resolution will be reflected in the configuration of the product.
  • reaction mixture was then treated with tetrazole (0.014 gram, 200 micromole) and 2-cyanoethanol (0.014 gram, 200 micromole). After a further hour at ambient temperature the resulting phosphite triester was oxidised with sulphur (0.5 gram) in pyridine (2 ml) at room temperature for 16 hours.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

De nouvelles phosphorothioates d'inositol ont la formule générale (I) C6H6(OH)n[(OPO2S)2-]m[(OPO2O)2-]6-m-n dans laquelle n représente zéro ou un nombre entier allant de 1 à 5 et, m représente un nombre entier allant de 1 à 6. Elles peuvent être préparées selon un procédé consistant à faire réagir un dérivé d'inositol ayant la formule générale II C6H6(OB)n[OP(OCH2CH2CN)2]6-n, dans laquelle n représente zéro ou un nombre entier allant de 1 à 5 et B représente un groupe protecteur d'hydroxyle, avec une solution de soufre élémentaire, qui peut être radioactive ou non, dans un solvant prévu à cet effet, et à éliminer les groupes protecteurs d'hydroxyle du produit de la réaction. Des esters de phosphates peuvent être préparés par oxydation du composé de formule II avec un peroxyde organique.New inositol phosphorothioates have the general formula (I) C6H6 (OH) n [(OPO2S) 2-] m [(OPO2O) 2-] 6-min in which n represents zero or an integer ranging from 1 to 5 and, m represents an integer ranging from 1 to 6. They can be prepared according to a process consisting in reacting an inositol derivative having the general formula II C6H6 (OB) n [OP (OCH2CH2CN) 2] 6-n, in which n represents zero or an integer ranging from 1 to 5 and B represents a hydroxyl protecting group, with an elemental sulfur solution, which may or may not be radioactive, in a solvent provided for this purpose, and to eliminate the hydroxyl protecting groups of the reaction product. Phosphate esters can be prepared by oxidation of the compound of formula II with an organic peroxide.

Description

INOSITOL PHOSPHATE ANALOGUES
This invention relates to analogues of inositol phosphate esters and to a method for the preparation thereof.
Inositol [C6H6(OH)6] is hexahydroxycyclohexane of which there are nine isomeric forms. Myo- inositol is cis-1,2,3,5-trans-4,6-hexahydroxycyclohexane.
Certain of the inositol phosphates are known, One well-known derivative of commercial importance is phytic acid (inositol hexaphosphoric acid). Also known are D-myo-inositol-1,3,4-trisphosphate , the 1,4,5-isomer and the 1,4,5,6- and 1,3,4,5-tetrakisphosphates. These molecules are of biological importance although their precise biological roles have not yet been fully elucidated. They may be isolated with some difficulty and in low yield from natural sources.
Synthesis of the 1,4,5-trisphosphate has been achieved, but not entirely satisfactorily, by phosphorylation using P(V) agents which methods often result in the formation of undesirable five-membered phosphate rings.
The biological significance of inositol phosphates is the subject of much current interest and research. One area in which the inositol phosphates have been found to be involved is in calcium ion transport mechanisms in cells. A need exists, then, for materials for conducting scientific research into the biochemistry of inositol phosphate esters and, of course, such materials may possess pharmacological utility for therapy of clinical conditions arising from malfunction of the inositol phosphate biochemistry.
According to the present invention there is provided an inositol phosphorothioate having the general formula I;
C 6H6 (OH)n [(OPO2S)2-]m [(OPO2O)2-]6-m-n (I)
in which n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6.
Thus, the present invention provides an inositol molecule in which one or more of its six hydroxyl groups is esterified by a phosphorothioate group, the remaining positions being occupied by hydroxyl or phosphate ester groups.
The sulphur atom, of the thioate group may be a radioisotope of sulphur to provide radiolabelled compounds for use as research reagents.
The present invention also provides a method of preparing an inositol phosphorothioate having the general formula I;
C6H6 (OH)n [(OPO2S)2-]m [(OPO2O)2-]6-m-n (I)
in which n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6, said method comprising reacting an inositol derivative having the general formula II ;
C6H6 (OB)n [OP(OCH2CH2CN)2] 6-n (II)
in which n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with a solution of elemental sulphur in a solvent therefor, and removing the protecting groups from the product of the reaction.
Preferably the hydroxyl-protecting group represented by B in formula II is a benzyl group. Alternatively a divalent group such as isopropylidene may be utilised when n is an even number and the hydroxyl groups are thereby protected in pairs..
Thus the compound of general formula II may have the alternative formulae IIA or IIB:
C6H6 (OBz)n [OP(OCH2CH2CN)2]6-n (IIA)
C6H6 (O-iPr'-O)m [OP(OGH2CH2CN)2]p (IIB)
in which Bz is a benzyl group, iPr' is an isopropylidenyl group, n is zero or an integer from 1 to 5, m is zero or 1 or 2 and p is 2 or 4 or 6.
It is to be noted that the compound of general formula II above may be oxidised with, for example a hydroperoxide such as tert- butylhydroperoxide, to form a compound having the formula VI;
C6H6 (OBZ)n [O P O (OCH2CH2CN)2]6-n (VI)
which may then be reduced to deprotect the hydroxy groups and form phosphate ester groups. The starting material, that is, the inositol derivative having the general formula II defined above, may be prepared by a method comprising reacting a compound having the general formula III:
C6H6 (OB)n (OH)6-n (III)
in which n and B are as defined hereinabove, with chloro (2-cyanoethoxy) -N, N-diisopropylamino phosphine, which has the formula IV:
(iPr)2 N P (Cl) OCH2CH2CN (IV)
in which iPr represents an isopropyl group, to obtain a compound having the general formula V:
C6H6 (OB)n [OP(OCH2GH2CN) N (iPr)2]6-n (V) in which n, B and iPr are as defined hereinabove; and reacting the compound of formula V with terazole and 2-cyanoethanol to form the said compound of general formula I
The benzylated inositol starting material (formula III above) may be prepared from inositol, via the isopropylidene derivatives, according to the method described in J. Gigg, R. Gigg, S. Payne & R. Conant;
Carb. Res,, 140, cl, (1985); J. Chem. Soc. Perk. Trans., I, (1987), 423. The isopropylidene-containing starting materials and their preparation are described in J. Gigg, R. Gigg, S. Payne & R. Conant; Carb. Res., 142, 132 (1985) Concerning the reagent having the formula IV, reference is directed to N.D. Sinha, J.Biernat, J. McManus & H. Koester; Nucl. Acids Res., 12, 4539 (1984). The principal intended use of this reagent is for the synthesis of polynucleotides: see, for example, European Patent Application Number 35,719 and United States Patent Numbers 3,534,017; 4,415,732 and 4,458,066.
The present invention also provides a method of preparing an inositol phosphate having the general formula I;
C 6H6 (OH)n [(OPO2S)2-]m [(OPO2O)2-]6-m-n (I)
in which n is zero or an integer from 1 to 5 and, m is zero, said method comprising reacting an inositol derivative having the general formula II;'
C6H6 (OB)n [OP(OCH2CH2CN)2]6-n (II)
in which n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with an organic peroxide, and removing the protecting groups from the product of the reaction.
The organic preroxide is preferably tert-butyl hydroperoxide.
Reference is made to the accompanying drawing which shows the reaction scheme of the invention using the tetrabenzylated derivative of myo-inositol as an example. The reagents involved in the steps identified in the drawing as (i) to (iv) were as follows: (i) (iPr)2 N P (Cl) OCH2CH2CN, C2H5N(iPr)2 in dichloromethane);
(ii) Tetrazole, HOCH2CH2CN in dichloromethane;
(iii) tert-BuOOH(for X=O) : sulphur in pyridine (for X=S);and,
(iv) NH4OH at 60°C followed by sodium in liquid NH3.
The invention will now be described, by way of illustration, in the following Examples.
EXAMPLE 1
(+,-)- 1,2,4-tri-O-benzyl-myo-inositol (0.20 mmole) was treated with 0.66 mmole of chloro (2-cyanoethoxy)- N,N diisopropylamino phosphine and diisopropylethylamine ((0.60 mmole) in dichloromethane to yield the trisphosphoramidite. Reaction of the trisphosphoramidite with tetrazole and 2-cyanoethanol yielded the trisphosphite triester in about 90% yield. 31P NMR spectroscopy showed 5Jpp spin-spin coupling in the form of an AB system for two of the phosphite triesters confirming the phosphitylation of the vicinal 4,5-diol system.
Oxidation with anyhydrous tert-butyl hydroperoxide afforded quantitatively the trisphosphate ester and finally deblocking using sodium in liquid ammonia effected reductive removal of the benzyl groups and removal of the 2-cyanoethyl groups by beta-elimination to give the trisphosphate product which was purified by ion-exchange chromatography. In order to remove contaminating traces of other inositol phosphates the product was further purified by HPLC. DL-myo-inositol- 1,4,5-trisphosphate was obtained in about 50% yield. The 31P and 1H NMR spectra and the SAB mass spectrum of the purified product corresponded with that reported for the same compound isolated from natural sources.
EXAMPLE 2
(+,-)-1,2,3,4-tetra-O-benzyl myo-inositol was treated with 2 equivalents of chloro(2-cyanoethoxy)- N,N diisopropylamino phosphine in dichloromethane to yield the bisphosphoramidite. Treatment of the bisphosphoramidite with tetrazole and 2-cyanoethanol gave the bisphosphite triester. 31P NMR spectroscopy showed that about 90% of the phosphorus could be accounted for by an AB system assignable to the 4, 5-bisρhosphite triester system.
Oxidation of the bisphosphite triester with tert-butyl hydroperoxide gave the bisphosphate triester. Ammonolysis removed the 2-cyanoethyl groups (heating to 60°C for 3 hours was necessary as mild ammonolysis only removed one of the 2-cyanoethyl groups from each phosphotriester) and treatment with sodium in liquid ammonia quantitatively removed the benzyl groups to give (+, -)myo-inositol 4,5-bisphosρhate.
EXAMPLE 3
The 4,5-bisphosphite triester, prepared as described in Example 2 above, was reacted with a solution of sulphur in pyridine to yield the bisphosphoro-thioate triester and subsequent removal of the protecting groups using sodium in liquid ammonia yielded (+,-)myo-inositol 4,5-bisphosρhorothioate. For particular uses, the sulphur may be radioactive.
EXAMPLE 4
(+ , -) -1,2,4,5-Bisisopropylidene-myo-inositol (0.325 mmole) was reacted with chloro(2-cyanoethoxy)-N,N diisopropylamino phosphine (0.715 mmole) and diisopropylethylamine (0.715 mmole) in dichloromethane (1 ml) for one hour to yield the bisphosphoramidite. Reaction of the phosphoramidite with tetrazole and 2-cyanoethanol (0.715 mmole of each) gave the 1,4-bisphosphite triester. Oxidation with tert-butyl hydroperoxide (1 ml) gave the bisphosphate triester.
Ammonolysis (2 hours at 65ºC) removed the 2-cyanoethyl groups and treatment of the ammonium salt in water with excess Dowex (Trade Mark) H+ ion-exchange resin for one hour gave myo-inositol 1,4-bisphosρhate (80%) which was converted into the solid cyclohexylammonium salt.
EXAMPLE 5
The bisphosphite triester, obtained as described in Example 4 above, (0.325 mmole) was oxidised using sulphur (200 mg) in pyridine (2 ml). The mixture was filtered, the solvent evaporated and the residue dissolved in methanol. Ammonolysis (3 hours at 65°C) gave the bisphosphorothioate and treatment with Dowex (Trade Mark) H+ ion-exchange resin for 3 hours followed by evaporation and addition of ammonia gave the crude ammonium salt as a gum which, on trituration with methanol, gave the ammonium salt of (+,-)-inositol 1,4-bisphosphorothioate as a white solid (51%). EXAMPLE 6
In analogous manner, (+) -1,2,4-tri-O-benzyl-myo- inositol was converted to the corresponding tri [di(2-cyanoethyl)]phosphite via the phosphoramidite as previously described and then oxidised using sulphur in pyridine. Complete deprotection of all the protecting groups was accomplished using sodium in liquid ammonia, the 2-cyanoethyl groups being removed by beta-elimination and the benzyl groups cleaved to yield a crude product.
Purification of the crude product on a column of DEAE Sephadex A-25 (Trade Mark) using a linear gradient of triethylammonium bicarbonate gave DL-myo- inositol- 1,4,5-trisphosphorothioate eluting at around 800mM buffer in a yield of about 25%. [31P NMR (D2O, pH9) proton coupled dp 3d, 42.0 (JPH=8.0 Hz); 44.9 (JPH=9.3 Hz); 45.1 (JPH=9.3 Hz)] (shown in Fig.2). The proton-coupled 31P NMR spectrum was similar to that reported for authentic D-myo-inositol-1,4,5-trisphosphate and its synthetic DL-isomer except that the resonances were shifted about 40ppm downfield as would be expected for the phosphorothioates.
In biological evaluation of trisphosphorothioate, using rat cerebellum membrane receptor-binding assay specific for myo-inositol-1,4,5-trisρhosphate, the trisphosphorothioate was found to have a high affinity for such receptors, indicating the potential of the sulphur analogues in studies on receptor-linked phosphoinositide metabolism. Additionally it was found to release calcium from permeablised cells as a full agonist with an EC50 of only three times higher than the 1,4,5-trisphosphate. EXAMPLE 7
(±)-1, 2:4,5-Diisopropylidene-myo-inositol (0.325 mmole) was reacted with chloro(2-cyanoethoxy)- N,N diisopropylamino phosphine (0.715 mmole) and diisoproplyamine (0.715 mmole) in dichloromethane for one hour at ambient temperature to yield the corresponding bisphophoramidite. [dP(CH2Cl2) 4s, 152.24, 152.30, 152.67, 152.71]. 31P NMR resonances corresponding to unequal pairs of epimers were observed, on account of the two chiral phosphorus centres (intensity ratios, downfield pair: upfield pair, approximately 2:1)
Reaction of the bisphosphoramidite with tetrazole and 2-cyanoethanol (0.715 mmole of each) gave the bisphosphite triester. [dP(CH2Cl2) 2s, 138.8, 139.61].
The bisphosphite triester (0.325 mmole) was oxidised to the bisphosphorothioate ester using sulphur (200 mg) in pyridine (2 ml). The reaction mixture was filtered, the liquid evaporated and the residue dissolved in methanol [dP (MeOH) 2s, 65.85, 67.41]. Ammonolysis (3 hours at 65ºC) gave a bisphosphorothioate possessing two isopropylidene ketals [dP (D2O, pH 12) proton coupled, d, 43.16, J=10.96 Hz], and treatment with excess Dowex H (Trade Mark) ionexchange resin in water for 3 hours followed by evaporation and addition of ammonia gave a crude gum, which on trituration with methanol gave the ammonium salt of (±)-myo-inositol-1,4-bisphosphorothioate (51% yield) [dp (D2O, pH 12) proton coupled, d, 44.82,
J=8.52 Hz; d, 46.34, J=9.74 Hz] contaminated with only minor amounts of impurities. Final purification was effected on a column of DEAE Sephadex (Trade Mark) as described above. To myo-inositol-1,4-bisρhosphorothioate (25 micromoles) dissolved in 100 mM glycine buffer at pH 10.1 containing 1 mM MgCl2 and 0.1 mM ZnCl2 (0.5 ml, ca. 50% D2O) in a precision NMR tube was added alkaline phosphatase (30 microlitres, 25 units) and the
31 P spectrum was monitored. No change in the NMR spectrum was observed when monitored over a few hours and overnight incubation (23 hours) showed only the two peaks assignable to the bisphosphorothioate. In comparison, using the bisphosphate ester in a similar experiment, clear evidence was observed for the degradation of the bisphosphate to the monophosphates and inorganic phosphate by the phosphatase. Additionally it was found to be resistant to the action of the inositol 1,4,5-trisphosphate-specific
5-phosphatase enzyme, thus demonstrating the phosphatase resistance of the phosphorothioate analogues.
EXAMPLES 8 to 15
By methods analogous to those described in the preceding Examples, the following inositol phosphorothioates may be prepared:
8. myo-inositol-1-phosphorothioate.
9. myo-inositol-1,4,-bisphosphorothioate.
10. myo-inositol-1,4,5-triρhosρhorothioate. 11. myo-inositol-1,4,5-triphosρhorothioate.
12. myo-inositol-1,3,4,5-tetrakisphosphorothioate.
13. myo-inositol-1,4,5,6-tetrakisphosphorothioate.
14. myo-inositol-1,3,4,5,6-pentakisphosphorothioate.
15. myo-inositol-1,2,3,4,5,6-hexakisphosphorothioate
The optical configuration of these products is determined by the optical configuration of the starting materials. If the precursors of the products are optically resolved, the resolution will be reflected in the configuration of the product. EXAMPLE 16
(±) -2,3,6-tri-O-benzyl-1,4-(2,2,2-trichloroethyl phosphate) -myo-inositol (0.091 gram, 80 micromole) was dissolved in dry acetonitrile (1 ml). To this solution were added N,N-diisopropylamine (0.011 gram, 80 micromole) and chloro(2-cyanoethyl)-N,N-diisopropylamino phosphine (0.024 gram, 100 micromole). The mixture was allowed to stand at room temperature for one hour. The reaction mixture was then treated with tetrazole (0.014 gram, 200 micromole) and 2-cyanoethanol (0.014 gram, 200 micromole). After a further hour at ambient temperature the resulting phosphite triester was oxidised with sulphur (0.5 gram) in pyridine (2 ml) at room temperature for 16 hours.
All volatile products were evaporated and the residue dissolved in dry dioxan (1ml). This solution was added to a solution of sodium (0.5 gram) in liquid ammonia (50 ml). After 10 minutes the reaction was quenched with methanol and the ammonia allowed to evaporate. The residue was taken up in water (100 ml) and treated with. Dowex (Trade Mark) H ion-exchange resin until the solution was acidic. The resin was removed by filtration and the solution rendered basic with triethylamine. The solvent was removed by evaporation and the resulting residue, after dissolution in water, was chromatographed on a column of DEAE Sephadex (Trade Mark) A-25 resin (12 x 2.5 cm) using a gradient of triethylammonium bicarbonate (600 ml of each of 150 mM to 1M).
DL-myo-inositol-1,4-bisphosphate-5-phosphorothioate was eluted around 550 mM buffer as the triethylammonium salt. Evaporation of the pooled fractions gave the product as a glass (35 micromole, 44% , 31P NMR, d
(H2O) 2.6, 4.6, (PO2 3-), 45.0 (PSO2 2-).

Claims

1. An inositol phosphorothioate having the general formula I ;
C6H6 (OH)n [ (OPO2S) 2-]m [(OPO2O)2-]6-m-n (I)
in which n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6.
2. myo-inositol-1-phosphorothioate.
3. myo-inositol-1,4,-bisphosphorothioate.
4. myo-inositol-1,4,5-trisρhosphorothioate
5. myo-inositol-1,4,5-trisρhosρhorothioate.
6. myo-inositol-1,3,4,5-tetrakisρhosρhorothioate.
7. myo-inositol-1,4,5,6-tetrakisphosphorothioate. myo-inositol-1,3,4,5,6-pentakisphosphorothioate.
myo-inositol-1,2,3,4,5,6-hexakisphosphorothioate
10. An isositol phosphorothioate as claimed in any of the preceding claims in which a suplhur atom is a radioisotope.
11. A method of preparing an inositol phosphorothioate having the general formula I;
C6H6, (OH)n [(OPO2S)2-]m [(OPO2O)2-] 6-m-n (I)
in which n is zero or an integer from 1 to 5 and, m is an integer from 1 to 6, said method comprising reacting an inositol derivative having the general formula II;
C6H6 (OB)n [OP(OCH2CH2CN)2]6-n (II)
in which n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with a solution of elemental sulphur in a solvent therefor, and removing the hydroxyl-protecting groups from the product of the reaction.
12. A method as claimed in claim 11, in which the hydroxyl-protecting group represented by B in formula II is a benzyl group, whereby the compound of formula II has the formula IIA:.
C 6H6 (OBz)n [OP(OCH 2CH 2GH)]6-n (IIA) in which Bz is a benzyl group, and n is zero or an integer from 1 to 5.
13. A method as claimed in claim 11 or 12, in which n is an even number and the group represented by B in formula II is an isopropylidene group, whereby the compound of formula II has the formula IIB:.
C6H6 (O-iPr'-O)m [OP(OCH2CH2CN)]p (IIB)
in which iPr' is an isopropylidenyl group, m is zero or 1 or 2 and p is 2 or 4 or 6.
14. A method as claimed in claim 11 or 12 or 13, in which the reaction with sulphur is effected by treatment of the compound of formula II with a solution of sulphur in pyridine.
15. A method as claimed in any of claims 11 to 14, in which the protecting groups are removed by treatment with sodium and liquid ammonia.
16. A method as claimed in any of claims 11 to 15, in which the inositol derivative having the general formula II defined in claim 10, is prepared by a method comprising reacting a compound having the general formula III:
C6H6 (OB)n (OH) 6-n (III)
in which n and B are as defined hereinabove, with chloro(2-cyanoethoxy)-N,N-diisopropylamino phosphine, which has the formula IV:
(iPr)2 N P (Cl) OCH2CH2CN (IV) in which iPr represents an isopropyl group, to obtain a compound having the general formula V:
C6H6 (OB)n [OP(OCH2CH2CN) N ( iPr )2] 6-n (V)
in which n, B and iPr are as defined hereinabove; and reacting the compound of formula V with terazole and 2-cyanoethanol to form the said compound of general formula II
17. A method as claimed in any of claims 11 to 16, in which the compound having the general formula II is reacted with an organic oxidising agent followed by removal of the hydroxyl-protecting groups from the product of the reaction, to give a product of general formula I in which one or more of the substituents is a phosphate ester group.
18. A method as claimed in claim 17, in which the oxidising agent is tert-butylhydroperoxide.
19. Pharmaceutical preparations containing as active principle an inositol phosphorothioate having the general formula I defined in claim 1.
20. A method of preparing an inositol phosphate having the general formula I;
C 6H6, (OH)n [(OPO2S)2-]m [(OPO2O)2-]6-m-n (I)
in which n is zero or an integer from 1 to 5 and, m is zero, said method comprising reacting an inositol derivative having the general formula II;
C6H6 (OB)n [OP(OCH2CH2CN)2]6-n (II) in which n is zero or an integer from 1 to 5 and B represents a hydroxyl-protecting group, with an organic peroxide, and removing the protecting groups from the product of the reaction.
21. A method as claimed in claim 20 in which the organic peroxide is tert-butyl hydroperoxide.
EP88902179A 1987-03-11 1988-03-10 Inositol phosphate analogues Withdrawn EP0354904A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8705811 1987-03-11
GB878705811A GB8705811D0 (en) 1987-03-11 1987-03-11 Inositol derivatives

Publications (1)

Publication Number Publication Date
EP0354904A1 true EP0354904A1 (en) 1990-02-21

Family

ID=10613789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP88902179A Withdrawn EP0354904A1 (en) 1987-03-11 1988-03-10 Inositol phosphate analogues

Country Status (5)

Country Link
EP (1) EP0354904A1 (en)
JP (1) JPH02502535A (en)
CA (1) CA1309415C (en)
GB (1) GB8705811D0 (en)
WO (1) WO1988007047A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0579957A1 (en) * 1987-07-02 1994-01-26 3i RESEARCH EXPLOITATION LIMITED Preparation of isomers of myoinositol derivatives
RU2465893C2 (en) * 2006-08-02 2012-11-10 Йоханнес Гутенберг-Университет Майнц Anti-poisoning medication
US20120258936A1 (en) * 2011-04-06 2012-10-11 The Board Of Regents Of The University Of Texas System Inositol hexakisphosphate analogs and uses thereof
CA2849426C (en) * 2011-09-29 2020-03-24 Eth Zurich Pharmaceutical compounds for use in the therapy of clostridium difficile infection

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465951B (en) * 1984-10-23 1991-11-25 Perstorp Ab ISOMER OF INOSITOL TRIPHOSPHATE PHARMACEUTICAL STATEMENTS FOR SALT FOR USE AS THERAPEUTIC OR PROPHYLACTIC AGENTS AND COMPOSITIONS THEREOF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8807047A1 *

Also Published As

Publication number Publication date
JPH02502535A (en) 1990-08-16
GB8705811D0 (en) 1987-04-15
WO1988007047A1 (en) 1988-09-22
CA1309415C (en) 1992-10-27

Similar Documents

Publication Publication Date Title
Mitchell et al. Bioreversible protection for the phospho group: bioactivation of the di (4-acyloxybenzyl) and mono (4-acyloxybenzyl) phosphoesters of methylphosphonate and phosphonoacetate
Weimann et al. Studies on Polynucleotides. XVII. 1 On the Mechanism of Internucleotide Bond Synthesis by the Carbodiimide Method 2
Potter et al. Chemistry of inositol lipid mediated cellular signaling
Lindh et al. A general method for the synthesis of glycerophospholipids and their analogs via H-phosphonate intermediates
Vacca et al. The total synthesis of myo-inositol polyphosphates
AU651835B2 (en) Phosphorous prodrugs
Lampe et al. Synthesis of selective non-Ca2+ mobilizing inhibitors of D-myo-Inositol 1, 4, 5-trisphosphate 5-phosphatase
Cooke et al. Synthesis of DL-Myo-inositol 1, 4, 5-triphosphate
Stawinski et al. Nucleoside H-phosphonates. 12. Synthesis of nucleoside 3'-(hydrogen phosphonothioate) monoesters via phosphinate intermediates
Thomson et al. Synthesis, bioactivation and anti-HIV activity of the bis (4-acyloxybenzyl) and mono (4-acyloxybenzyl) esters of the 5′-monophosphate of AZT
Stawinski et al. Nucleoside H-phosphonates. 14. Synthesis of nucleoside phosphoroselenoates and phosphorothioselenoates via stereospecific selenization of the corresponding H-phosphonate and H-phosphonothioate diesters with the aid of new selenium-transfer reagent, 3H-1, 2-benzothiaselenol-3-one
Imai et al. Bis (2, 2, 2-trichloroethyl) phosphorochloridite as a reagent for the phosphorylation of oligonucleotides: preparation of 5'-phosphorylated 2', 5'-oligoadenylates
Turcotte et al. Cytotoxic liponucleotide analogs: I. Chemical synthesis of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety
Oza et al. A mild preparation of protected phosphate esters from alcohols
Holý et al. Preparation of 5'-O-phosphonylmethyl analogues of nucleoside-5'-phosphates, 5'-diphosphates and 5'-triphosphates
Stock Synthesis of phosphonate analogs of thymidine di-and triphosphate from 5'-O-toluenesulfonylthymidine
EP0354904A1 (en) Inositol phosphate analogues
Lin et al. Phospholipids chiral at phosphorus. 18. Stereochemistry of phosphatidylinositide-specific phospholipase C
Hamblin et al. myo-Inositol phosphorothioates, phosphatase-resistant analogues of myo-inositol phosphates. Synthesis of DL-myo-inositol 1, 4-bisphosphate and DL-myo-inositol 1, 4-bisphosphorothioate
Mitchell et al. Prodrugs of phosphonoformate: Products, kinetics and mechanisms of hydrolysis of dibenzyl (methoxycarbonyl) phosphonate
Baddiley et al. 550. Phosphorylation through glyoxalines [iminazoles] and its significance in enzymic transphosphorylation
Richard et al. Stereochemical course of phosphoanhydride synthesis
Sawabe et al. Use of 2-trimethylsilylethyl as a protecting group in phosphate monoester synthesis
Martin et al. A general and efficient route to phosphorodithioate analogs of naturally occurring lipids
Shashidhar et al. Synthesis of phosphonate derivatives of myo-inositol for use in biochemical studies of inositol-binding proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19890908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: 3I RESEARCH EXPLOITATION LIMITED

RBV Designated contracting states (corrected)

Designated state(s): BE DE FR GB IT NL

RBV Designated contracting states (corrected)

Designated state(s): BE DE FR GB IT NL

17Q First examination report despatched

Effective date: 19920915

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930126